Companies: 10,795·Total market cap: $144.5T
Inozyme Pharma, Inc.

Inozyme Pharma, Inc.

INZYNASDAQHealthcare
$4.00
+$0.01(+0.25%)
Market Cap$258247200
P/E Ratio
52W High$6.24
52W Low$0.721

Inozyme Pharma, Inc. (INZY) Revenue

Annual & quarterly revenue history · segment & region breakdown

INZY · revenue · updated Jun 10, 2026

Core revenue metrics

Inozyme Pharma, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
67 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Inozyme Pharma, Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
INZY revenue by year · INZY revenue history · INZY annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Inozyme Pharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Inozyme Pharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Inozyme Pharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

INZY revenue · 4 questions

INZY's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

INZY revenueINZY annual revenuewhat is INZY revenueINZY TTM revenue

Source: FMP · Inozyme Pharma, Inc. SEC filings · GAAP · Inozyme Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026